Cite
HARVARD Citation
Al‐Kali, A. et al. (2023). A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. American journal of hematology. 98 (3), pp. 472-480. [Online].